ijms-logo

Journal Browser

Journal Browser

Advanced Molecular Research in Cardiology and Treatment Approaches

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: 31 October 2025 | Viewed by 837

Special Issue Editor


E-Mail Website
Guest Editor
Toronto General Hospital Research Institute, 100 College St., Toronto, ON M5G 1L7, Canada
Interests: ischemic heart disease; cardiac regeneration; epigenetic regulation; cardiomyocyte proliferation

Special Issue Information

Dear Colleagues,

Ischemic heart disease remains a leading cause of death worldwide, in part due to the adult heart’s limited regenerative capacity. Two broad approaches have been explored over the last twenty years in the field of cardiac regeneration: (i) the use of stem cells and (ii) the coaxing of endogenous CM to proliferate, both with limited success. Our research investigates the molecular constraints on cardiomyocyte (CM) proliferation after myocardial infarction (MI), focusing on the transcription factor TAp63 and the histone methyltransferase EzH2. We discovered that these two factors form a repressive complex in vivo that silences key mitotic genes in adult CM through coordinated transcriptional and epigenetic mechanisms.

Using both genetic and pharmacological approaches, we show that disrupting TAp63 or EzH2—either by cardiac-specific knockout or gapmer-mediated knockdown—induces robust CM proliferation, restores cell cycle progression, and improves cardiac function post-MI. Mechanistically, we demonstrate that TAp63/EzH2 directly repress genes such as Skp2 and Ect2 by depositing H3K27me3 marks at their promoters. Loss of this repression reactivates mitotic pathways necessary for regeneration. Moreover, we found that the Ras-Raf-Mek-Erk signaling pathway is required for Skp2-mediated p27KIP1 degradation and CM proliferation.

Together, our findings identify the TAp63/EzH2 complex as a key molecular brake on cardiac regeneration. By lifting this brake, we reveal a previously untapped capacity of the adult heart to repair itself through endogenous CM proliferation. These results offer compelling preclinical evidence that targeting TAp63/EzH2 may serve as a viable therapeutic strategy to enhance heart repair after MI.

Dr. Ludger Hauck
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • TAp63
  • EzH2
  • histone methyltransferase
  • cardiomyocyte proliferation
  • myocardial infarction
  • heart regeneration
  • heart repair
  • epigenetic regulation
  • cardiac regeneration
  • Skp2-p27KIP1 pathway

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

52 pages, 7055 KB  
Review
Translational Control in Cardiac Pathophysiology and Therapeutic Development: When mRNA Meets the Heart
by Uday K. Baliga, Liuqing Yang, Aleksandr Ivanov, Jack L. Schwartz, Feng Jiang, Eng-Soon Khor, Debojyoti Das, Lindsey Wainwright and Peng Yao
Int. J. Mol. Sci. 2025, 26(16), 7863; https://doi.org/10.3390/ijms26167863 - 14 Aug 2025
Viewed by 660
Abstract
Cardiac physiology and pathology have been extensively explored at the transcriptional level. Still, they are less understood at the translational level, including three major knowledge gaps: pathophysiological impact, molecular mechanisms, and therapeutic implications of translational control in cardiac biology and heart disease. This [...] Read more.
Cardiac physiology and pathology have been extensively explored at the transcriptional level. Still, they are less understood at the translational level, including three major knowledge gaps: pathophysiological impact, molecular mechanisms, and therapeutic implications of translational control in cardiac biology and heart disease. This review aims to provide a summary of the most recent key findings in this emerging field of translational control in heart health and disease, covering the physiological functions, disease pathogenesis, biochemical mechanisms, and development of potential RNA-based, translation-manipulating drugs. Translation of mRNA to protein is the final step in the central dogma for protein synthesis. Translation machinery includes a family of essential “housekeeping” factors and enzymes required for mRNA translation. These translation factors ensure the accurate processing of mRNA to protein according to the genetic code and maintain the optimal quality and quantity of cellular proteins for normal cardiac function. Translation factors also regulate the efficiency, speed, and fidelity of protein production and play a role in cardiac pathological remodeling under stress conditions. This review first introduces the techniques and methods used to study the translational regulation of gene expression in the cardiac system. We then summarize discoveries of a variety of pathophysiological functions and molecular mechanisms of translational control in cardiac health and disease, focusing on two primary symptoms, cardiac hypertrophy and fibrosis. In these sessions, we discuss the translational regulation directed by specific regulatory factors in cardiac physiology and how their genetic mutations, expression dysregulation, or functional alterations contribute to the etiology of heart disease. Notably, translational control exhibits extensive crosstalk with other processes, including transcriptional regulation, mitochondrial metabolism, and sarcomere homeostasis. Furthermore, recent findings have revealed the role of translational regulation in cardiomyocyte proliferation and heart regeneration, providing new approaches for creating regenerative medicine. Because transcript-specific translational regulation of both pathological and protective proteins occurs in heart disease, target-selective translation inhibitors and enhancers can be developed. These inhibitors and enhancers offer valuable insights into novel therapeutic targets and the development of RNA-based drugs for heart disease treatment. Full article
(This article belongs to the Special Issue Advanced Molecular Research in Cardiology and Treatment Approaches)
Show Figures

Figure 1

Back to TopTop